{
    "organizations": [],
    "uuid": "4af92a737543cc42d7868e3098251e0e3d7b5d47",
    "author": "",
    "url": "https://www.reuters.com/article/brief-baxter-announces-us-fda-approval-o/brief-baxter-announces-u-s-fda-approval-of-ready-to-use-bivalirudin-idUSASB0C1OY",
    "ord_in_thread": 0,
    "title": "BRIEF-Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 45 PM / Updated 11 minutes ago BRIEF-Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin Reuters Staff \nJan 22 (Reuters) - Baxter International Inc: \n* BAXTER ANNOUNCES U.S. FDA APPROVAL OF READY-TO-USE CARDIOVASCULAR MEDICATION BIVALIRUDIN \n* BAXTER INTERNATIONAL SAYS U.S. FDA APPROVED BIVALIRUDIN IN 0.9 PERCENT SODIUM CHLORIDE INJECTION \n* BAXTER INTERNATIONAL INC - BIVALIRUDIN IS EXPECTED TO LAUNCH IN UNITED STATES IN EARLY 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-01-22T15:42:00.000+02:00",
    "crawled": "2018-01-22T16:02:38.015+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "fda",
        "approval",
        "bivalirudin",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "baxter",
        "international",
        "inc",
        "baxter",
        "announces",
        "fda",
        "approval",
        "cardiovascular",
        "medication",
        "bivalirudin",
        "baxter",
        "international",
        "say",
        "fda",
        "approved",
        "bivalirudin",
        "percent",
        "sodium",
        "chloride",
        "injection",
        "baxter",
        "international",
        "inc",
        "bivalirudin",
        "expected",
        "launch",
        "united",
        "state",
        "early",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}